Saturday 17 October 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.
0.09
0.01
−10.00%
Follow CAPS
| Dec '16 | Dec '17 | Dec '18 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 3 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (179.60) | (4.19) | (4.90) | (5.67) |
P/S ratio |
— | — | 0.00 | 0.00 | 0.01 | 0.08 |
Altman Z″-Score (non-manufacturers) |
— | — | (419.24) | (11.76) | (13.66) | (14.93) |
P/FCF ratio |
— | — | 16.48 | 0.00 | 0.09 | 0.00 |
Beneish M-Score |
— | — | — | — | (3.01) | (3.81) |
P/Operating CF |
— | — | (2.29) | (0.36) | 0.13 | (9.25) |
P/B ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.31 |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | 0.00 | 0.00 | 0.33 | 0.57 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 33.67 | (1.29) | 3.82 | (6.01) |
EV/FCF |
— | — | 33.67 | (1.29) | 3.94 | (5.85) |
Quick Ratio |
2.30 | 6.41 | 5.45 | 0.16 | 0.22 | 0.24 |
Current Ratio |
2.73 | 6.90 | 5.85 | 1.07 | 1.02 | 1.00 |
Net Debt/EBITDA |
(0.21) | (0.66) | (47.25) | (21.70) | (43.98) | (2.69) |
Debt/Assets |
84.60% | 143.34% | 167.57% | 32.83% | 30.57% | 45.47% |
Debt/Equity |
(8.20) | (2.56) | (1.99) | 7.10 | (4.72) | 1.88 |
Asset Turnover |
0.00 | 0.00 | 1.31 | 1.79 | 0.90 | 0.95 |
Operating CF/Net income |
1.90 | 0.89 | (0.17) | (0.29) | (0.70) | 0.20 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.45) | (0.60) | (0.06) |
Interest Coverage |
— | — | — | (0.75) | (0.43) | (2.83) |
| (345.31%) | 350.65% | 35.80% | (961.44%) | 1,769.73% | (468.45%) | |
| (44.96%) | (127.59%) | (24.95%) | (21.17%) | (11.00%) | (44.49%) | |
ROIC |
(550.00%) | (1,105.26%) | 0.00% | (3.99%) | (3.51%) | (19.57%) |
Return on Tangible Assets |
(126.29%) | (149.49%) | (31.88%) | (200.10%) | (297.99%) | (1,014.10%) |
Average Days of Receivables |
— | — | 0.00 | 19.48 | 22.46 | 37.87 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 68.65% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 27.70% | 22.47% | 22.75% | 30.66% |
Intangible Assets out of Total Assets |
0.30 | 0.12 | 0.03 | 0.44 | 0.49 | 0.40 |
Share Based Compensation of Revenue |
0.00% | — | 0.75% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | (1.18) | (9.76) | (106.13) | (4.10) |
Graham Number |
— | — | 70.62 | 0.00 | 84.26 | 0.00 |
Earnings Yield |
— | — | (48.46%) | (873.35%) | (725.97%) | (497.26%) |
Free Cash Flow Yield |
— | — | 6.07% | (719.74%) | 1,061.68% | (116.71%) |
Revenue per Share |
0.00 | 0.00 | 36.76 | 306.81 | 284.75 | 8.81 |
Operating CF per Share |
(30.78) | (33.07) | 1.21 | 10.47 | 24.54 | (0.83) |
Capex per Share |
0.00 | 0.00 | 0.00 | (1.32) | (1.18) | (0.03) |
Free Cash Flow per Share |
(30.78) | (33.07) | 1.21 | 9.15 | 23.36 | (0.86) |
Cash per Share |
17.07 | 27.01 | 24.65 | 0.33 | 0.07 | 0.14 |
Shareholders Equity per Share |
(2.98) | (18.62) | (22.87) | 15.46 | (19.40) | 2.34 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.98) | (18.62) | (22.87) | 15.46 | (19.40) | 2.34 |
Free Cash Flow |
(1.26) | (1.56) | 0.07 | 1.44 | 3.68 | (4.57) |
Working Capital |
0.53 | 1.17 | 1.19 | 1.11 | 0.25 | 0.08 |
Capital Expenditures |
— | — | — | (0.21) | (0.19) | (0.16) |
Net Current Asset Value |
(0.47) | (1.07) | (1.28) | (33.18) | (37.47) | (15.92) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.26 | 0.19 | 1.23 |
Cash ROIC |
(79.89%) | (59.02%) | 2.57% | 7.29% | 32.33% | (12.51%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 16.80 | 12.30 |
Accounts Payable Turnover |
0.00 | 0.00 | 1.15 | 27.48 | 12.01 | 8.74 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 3.02 | 2.70 |
Average Days of Payables |
0.00 | 0.00 | 352.07 | 24.26 | 34.16 | 50.14 |
Days of Inventory on Hand |
— | — | 0.00 | 129.54 | 99.61 | 172.56 |
Average Receivables |
— | — | — | — | 2.67 | 3.81 |
Average Payables |
0.25 | 0.22 | 0.22 | 1.41 | 2.94 | 4.13 |
Average Inventory |
— | — | — | — | 11.69 | 13.35 |
Average Assets |
1.47 | 1.38 | 1.52 | 27.09 | 49.96 | 49.30 |
Average Common Equity |
0.19 | (0.50) | (1.06) | 0.60 | (0.31) | 4.68 |
Columns are period end dates